ERBB2 and breast cancer: Firstly, we reported on the treatment results of cN+ breast cancer patients, which included very up-to-date NST treatment regimens and resulted in high rates of AXpCR, which is the most important prognostic factor for the long-term outcome in HER2-positive and TN subtypes [42].